If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Ukrainian media reported that the HUR carried out a cyberattack on Russian internet providers in Crimea. The HUR revealed that a crowd-sourced satellite purchased in 2022 was responsible for taking some 4,200 images using Synthetic Aperture Radar, saying that this led to the destruction of over 1,500 Russian targets worth “billions” of dollars.
The laboratory industry is a part of the broader healthcare and health technology industry. Companies exist at various levels, including clinical laboratory services, suppliers of instrumentation equipment and consumable materials, and suppliers and developers of diagnostic tests themselves (often by biotechnology companies). Clinical laboratory services includes large multinational corporations such LabCorp, Quest Diagnostics, and Sonic Healthcare but a significant portion of revenue, estimated at 60% in the United States, is generated by hospital labs. In 2018, the total global revenue for these companies was estimated to reach $146 billion by 2024. Another estimate places the market size at $205 billion, reaching $333 billion by 2023. The American Association for Clinical Chemistry (AACC) represents professionals in the field. Clinical laboratories are supplied by other multinational companies which focus on materials and equipment, which can be used for both scientific research and medical testing. The largest of these is Thermo Fisher Scientific. In 2016, global life sciences instrumentation sales were around $47 billion, not including consumables, software, and services. In general, laboratory equipment includes lab centrifuges, transfection solutions, water purification systems, extraction techniques, gas generators, concentrators and evaporators, fume hoods, incubators, biological safety cabinets, bioreactors and fermenters, microwave-assisted chemistry, lab washers, and shakers and stirrers.
== Effectiveness == While methadone clinics are generally considered to be effective treatment options for patients addicted to opioids, especially when other interventions have failed, there is controversy surrounding the placement of methadone clinics. There is a perception that the presence of the clinics attracts crime to surrounding areas. However, one study by the University of Maryland School of Medicine found that crime rates do not increase when a methadone clinic is opened. Another study by University of Pennsylvania found within a 200 m radius, the presence of a methadone clinic causes a significant decrease in property and total crime but a significant increase in drug and violent crime. A 2004 GAO study notes that placement of clinics can impede recovery and exacerbate relapse: "Although these clinics are intended to help those in need of rehabilitation, patients who seek treatment must navigate their way to and from the clinics in an environment in which illegal sales of narcotics are daily occurrences. The efforts of patients who are seeking rehabilitation, and clinic professionals who serve them, are significantly undermined by this criminal activity that surrounds them." Between 70 and 90% of patients who discontinue methadone maintenance will relapse. The high relapse rate may be partially due to the severity of cases seen at methadone clinics, as well as the long-term effects of opioid use. Some patients stay on methadone for the rest of their lives, which generates criticism regarding the effectiveness of the clinics.
== Adverse effects == The adverse-event profile of ceftolozane/tazobactam from two phase II trials (comparing either ceftolozane alone or in combination with tazobactam to ceftazidime or meropenem) suggests that ceftolozane/tazobactam is well tolerated. The most common adverse effects reported with ceftolozane/tazobactam are headache (5.8%), constipation (3.9%), hypertension (3%), nausea (2.8%), and diarrhea (1.9%).
Sources: en.wikipedia.org
Along with pancuronium bromide and potassium chloride, thiopental is used in 34 US states to execute prisoners by lethal injection. A large dose is given to ensure rapid loss of consciousness. Although death usually occurs within ten minutes of the beginning of the injection process, some have been known to take longer. In December 2009, Ohio became the first state in the US to use a single dose of sodium thiopental for an execution, following the failed use of the standard three-drug cocktail during a prior execution, due to inability to locate suitable veins. Kenneth Biros was executed using the single-drug method. Washington became the second state in the US to use the single-dose sodium thiopental injections for executions. In September 2010, the execution of Cal Coburn Brown was the first in the state to use a single-dose, single-drug injection. His death was pronounced approximately one and a half minutes after the intravenous administration of five grams of the drug. After its use for the execution of Jeffrey Landrigan in the US, the United Kingdom introduced a ban on the export of sodium thiopental in December 2010, after it was established that no European supplies to the US were being used for any other purpose. The restrictions were based on "the European Union Torture Regulation (including licensing of drugs used in execution by lethal injection)".
== Discovery == Motilin was discovered by J.C. Brown when he introduced alkaline solution into duodena of dogs, which caused strong gastric contractions. Brown et al. predicted that alkali could either release stimulus to activate motor activity or prevent the secretion of inhibitory hormone. They isolated a polypeptide as a by-product from purification of secretin on carboxymethyl cellulose. They named this polypeptide "Motilin."
=== Analogues === A number of analogues of bupropion exist, such as hydroxybupropion, radafaxine, and manifaxine, among others. These compounds are norepinephrine–dopamine reuptake inhibitors (NDRIs) similarly to bupropion. The analogues of bupropion with the N-tert-butyl group removed or replaced with an N-methyl group, 3-chlorocathinone (3-CC) and 3-chloromethcathinone (3-CMC; clophedrone), respectively, are potent serotonin–norepinephrine–dopamine releasing agents (SNDRAs). They have been encountered as cathinone designer and recreational drugs. The analogue of bupropion with the N-tert-butyl group replaced with an N-cyclopropyl group is 3-chloro-N-cyclopropylcathinone (3Cl-CpC; PAL-433, RTI-6037-39). It is a hybrid serotonin releasing agent (SRA) and serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) and was being investigated for potential treatment of cocaine dependence.
The study also highlights economy-specific gap analyses, which illustrate gaps in policy coverage and estimate potential energy savings achieved through the adoption of world’s most comprehensive standards. Compliance Counts: A Practitioners Guidebook on Best Practice Monitoring, Verification, and Enforcement (MV&E) for Appliance Standards &Labeling The Guidebook, published in collaboration with Mark Ellis & Associates, is designed as a step-by-step manual for policymakers and S&L program administrators to design and implement a successful compliance regime. Drawing on the experiences of existing S&L programs worldwide, the Guidebook provides different approaches to implementing and improving all aspects of a compliance framework, including establishment of a legal basis for MV&E activities and enforcement options for non-compliance. According to the guidebook, effective compliance regimes: ensure that consumers receive the products they expect when making purchasing decisions; provide industry participants a fair market in which to operate; and safeguard current and future energy and greenhouse gas emissions savings from S&L programs, among other benefits. Energy Efficiency Labels and Standards: A Guidebook for Appliances, Equipment, And Lighting (also available in Chinese, Spanish and Korean) This guidebook is designed as a manual for government officials and others around the world responsible for developing, implementing, enforcing, monitoring, and maintaining energy efficiency labeling and standard-setting programs. Tools
Pills, i.e. tablets or capsules Liquids such as syrups, solutions, elixers, emulsions, and tinctures Liquids such as decoctions and herbal teas Orally disintegrating tablets Lozenges or candy (electuaries) Thin films (e.g., Listerine Pocketpaks, nitroglycerin) to be placed on top of or underneath the tongue as well as against the cheek Powders or effervescent powder or tablets, often instructed to be mixed into a food item Plants or seeds prepared in various ways such as a cannabis edible Pastes such as high fluoride toothpastes Gases such as oxygen (can also be delivered through the nose)
Sources: en.wikipedia.org
=== Zika outbreak === While Zika has not been reported in India (as of 6 February 2016), on 3 February 2016, Dr Lal PathLabs and other competing pathology labs announced they were preparing Zika test kits. Dr Lal PathLabs reported they plan to sell their kits for Rs 4500 (€60). However, several days later IndiaToday reported: "the Union Ministry of Health pulled up private players, saying they cannot cash in on a public health emergency" and also reported that Dr. Vandana Lal (executive director of Dr Lal PathLabs) stated: "We don't want to talk on this matter. We don't have any tests for Zika virus and we are also not importing any test kits for the same. If at all we plan to do something, we will take the government's prior permission."
Ulrich Hersel; Claudia Dahmen; Horst Kessler (2003). "RGD modified polymers: biomaterials for stimulated cell adhesion and beyond". Biomaterials. 24 (24): 4385–4415. doi:10.1016/s0142-9612(03)00343-0. PMID 12922151. Wikidata Q34223126. Marco Arnold; Elisabetta A Cavalcanti-Adam; Roman Glass; Jacques Blümmel; Wolfgang Eck; Martin Kantlehner; Horst Kessler; Joachim P Spatz (2004). "Activation of integrin function by nanopatterned adhesive interfaces". ChemPhysChem. 5 (3): 383–388. doi:10.1002/cphc.200301014. PMID 15067875. Wikidata Q44832858. Kessler, Horst (July 1982). "Conformation and Biological Activity of Cyclic Peptides". Angewandte Chemie International Edition in English. 21 (7): 512–523. doi:10.1002/anie.198205121. ISSN 0570-0833. Dechantsreiter MA; Planker E; Mathä B; Lohof E; Hölzemann G; Jonczyk A; Goodman SL; Kessler H (1999). "N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists". Journal of Medicinal Chemistry. 42 (16): 3033–3040. doi:10.1021/jm970832g. PMID 10447947. Wikidata Q30580638. Elisabetta A Cavalcanti-Adam; Tova Volberg; Alexandre Micoulet; Horst Kessler; Benjamin Geiger; Joachim Pius Spatz (2007). "Cell spreading and focal adhesion dynamics are regulated by spacing of integrin ligands". Biophysical Journal. 92 (8): 2964–2974. doi:10.1529/biophysj.106.089730. PMC 1831685. PMID 17277192. Wikidata Q30479140. Kessler, Horst (2023). NMR: Mein Kompass in der Organischen und Medizinischen Chemie [NMR: my compass in organic and medicinal chemistry]. Berlin: GNT Publishing GmbH. ISBN 978-3-86225-132-2.
== Bibliography == Lytle, Charles F.; Meyer, John R. (May 21, 2004). General Zoology Laboratory Guide (Fourteenth ed.). New York: McGraw-Hill. ISBN 978-0-07-234900-9. Müller, Werner E.G. (February 2003). "The Origin of Metazoan Complexity: Porifera as Integrated Animals". Integrative and Comparative Biology. 43 (1): 3–10. CiteSeerX 10.1.1.333.3174. doi:10.1093/icb/43.1.3. JSTOR 3884834. PMID 21680404. {{cite journal}}: Cite uses deprecated parameter |citeseerx= (help)
== Adverse effects == In September 2020, the US Food and Drug Administration (FDA) required the boxed warning be updated for all benzodiazepine medicines to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.